Standard BioTools Inc. (ticker: not provided), a leader in the life sciences industry, has reported a 2% year-over-year revenue growth for the first quarter of 2024, primarily driven by its SomaScan service revenue.
The company has successfully reduced its non-GAAP operating expenses by 26% and improved its adjusted EBITDA by 45% on a pro forma combined basis. Achieving ahead of schedule, Standard BioTools anticipates realizing $50 million of the projected $80 million in operating synergies by year-end.
Despite economic headwinds causing a 12% decline in Standard BioTools’ revenues, the company reaffirms its full-year revenue guidance of $200 million to $205 million for 2024 and targets approximately $300 million in revenue by 2026. The company is committed to reducing cash burn and accelerating profitability while expanding its commercial and R&D efforts.
Key Takeaways
- Standard BioTools reports a 2% increase in year-over-year revenue, with a significant contribution from SomaScan services.
- Non-GAAP operating expenses saw a 26% reduction, and adjusted EBITDA improved by 45%.
- The company is on track to achieve $50 million of the projected $80 million in operating synergies by the end of the year.
- Full-year revenue guidance for 2024 remains at $200 million to $205 million.
- Aiming for $300 million in revenue by 2026, the company is focusing on profitability and growth initiatives.
Company Outlook
- Standard BioTools is focused on reducing cash burn and expects to see reduced cash outlays in future quarters.
- The company has terminated its share buyback program to support its business and fund potential M&A opportunities.
- A partnership with Illumina (NASDAQ:) serves as a long-term growth driver, with an upfront payment of $30 million from Illumina pending recognition as revenue.
Bearish Highlights
- Standard BioTools faced a 12% revenue decline due to economic challenges.
- Cash burn was high due to merger-related expenses, with $71 million in cash payments, including merger-related payments and debt retirement.
Bullish Highlights
- SomaScan’s technology is scalable and offers a competitive advantage over Olink in NGS readouts.
- The company is expanding its product offerings, including flow cytometry solutions and multi-omics services.
- Investments are being made in new growth opportunities, such as single SOMAmer reagent models.
Misses
- The company’s revenue from Standard BioTools’ standalone products declined by 12%.
- Despite high customer demand, growth for SomaLogic’s assay is project-based and subject to sample and budget availability.
Q&A Highlights
- CEO Michael Egholm expressed confidence in SomaLogic’s competitive edge and long-term supply of microfluidic technology to OEM partners.
- The company has 200 units in the field that rely on proprietary consumables and is pursuing additional OEM relationships.
- Upcoming conferences in June are seen as an opportunity for the company to connect with potential partners and investors.
In summary, Standard BioTools Inc. is navigating through a challenging economic landscape with strategic initiatives aimed at growth and operational efficiency.
The company’s partnership with Illumina and advancements in its product portfolio position it well for future success. The management team remains confident in their long-term strategy and the value they bring to stakeholders.
InvestingPro Insights
Standard BioTools Inc.’s commitment to growth and operational efficiency is reflected in the company’s financial health and market performance. Here’s a closer look at the company through the lens of InvestingPro data and tips:
InvestingPro Data highlights a significant revenue growth of 31.27% over the last twelve months as of Q1 2024. This is complemented by an impressive quarterly revenue growth of 81.3% in Q1 2024. Despite these strong growth figures, the company’s market capitalization stands at $917.91 million USD, suggesting a cautious market sentiment, potentially due to the company’s negative P/E ratio of -7.33 and an adjusted P/E ratio of -18.26 for the same period. Additionally, the price/book ratio as of Q1 2024 is 1.59, indicating that the company’s stock is trading at a relatively modest premium to its book value.
InvestingPro Tips offer further insights into Standard BioTools Inc.’s strategic financial moves. Management’s aggressive share buyback strategy could be a sign of confidence in the company’s future prospects. Moreover, the company holds more cash than debt on its balance sheet, which is a positive indicator of financial stability and flexibility. This is particularly important as the company aims to reduce cash burn and fund potential M&A opportunities. However, analysts do not anticipate the company will be profitable this year, reflecting the challenges ahead.
For readers interested in a deeper dive into Standard BioTools Inc.’s financial outlook, InvestingPro provides additional tips. There are currently 8 more InvestingPro Tips available, which can be accessed by visiting: (ticker not provided). Use coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription, offering valuable insights that can help investors make informed decisions.
Full transcript – Fluidigm Corp (NASDAQ:) Q1 2024:
Operator: Good day and welcome to the Standard BioTools Inc. First Quarter 2024 Earnings Conference Call. All participants will be in listen-only mode. [Operator Instructions] Please note, today’s event is being recorded. It’s now my pleasure to introduce David Holmes of Investor Relations.
David Holmes: Thank you, operator, and good afternoon, everyone. Welcome to Standard BioTools’ first quarter 2024 earnings conference call. Leading the call today is Michael Egholm, President and Chief Executive Officer; and Jeff Black, Chief Financial Officer. At the close of market today, Standard BioTools released its financial results for the quarter ended March 31, 2024. During the call, we will review our results and provide an update on our financial and operational performance, 2024 outlook, market trends and strategic initiatives. During this call, we will be making forward-looking statements about events and circumstances that have not yet occurred, including plans, projections of our business, our outlook for 2024 and future financial results, market trends and opportunities, and our expectations related to the combined operations with SomaLogic, including potential synergies and our business outlook for the combined company. These statements are subject to substantial risks and uncertainties that may cause actual events or results to differ materially from current expectations. The forward-looking statements on this call are based on information currently available to us and we disclaim any obligation to update these statements, except as may be required by law. During the call, we will also present some financial information on a non-GAAP basis. We believe these non-GAAP financial measures are useful in evaluating our core performance and as a baseline for assessing the future earnings potential of the company. We use these non-GAAP measures in our own evaluation of continuing operating performance. We encourage you to carefully consider our results on a GAAP and non-GAAP basis. A reconciliation between non-GAAP measures and their GAAP equivalents are provided in the tables accompanying today’s press release and as an appendix to today’s presentation slides. Please note, management will be referring to a slide presentation, including updated supplemental financial information within the webcast today. Following management’s remarks, we will host a Q&A session. Today’s slide presentation, along with a replay of the webcast, are available on the Investors section of our website. I would now like to turn the call over to Michael Egholm, President and CEO of Standard BioTools. Michael?
Michael Egholm: Thank you, David. We greatly appreciate everyone joining us on today’s call after successful first year of operation at Standard BioTools and now on to our first full quarter with an integrated SomaScan platform and SomaLogic team. Integrating technologies is hard, integrating culture is harder, but this has been one of the smoothest of the dozens I’ve been involved in over my career. Thanks go to the management team at SomaLogic who leaned in and helped the operating team at Standard through the hard work of bringing diverse organizations and platforms together. It is a testament to both cultures and clear recognition that each believed in the statement that we are indeed better together. So thank you to everyone involved. Now on to the realization of that teamwork on the power of scale in life sciences. We are ahead of plan on operating synergy targets and now expect to achieve $50 million of the $80 million expected synergies we projected by the end of this year. Next year, we’ll capture the remaining $30 million of that initial synergy target. As an organization, we are laser-focused on reducing cash burn and accelerating profitability, while maintaining long-term growth prospects through focused investments in our commercial organization and our R&D pipeline. Importantly, in addition to the operational, technological and financial leverage achieved in the combination, we are experiencing the early benefits of a more diversified revenue and customer mix. As our peers have discussed this quarter, it remains a challenging market for capital equipment sales in life sciences, perhaps one of the most challenging in the last decade. At Standard, while we’re seeing similar headwinds, our consumable and service business, which now includes SomaScan and its high quality service offering, are helping to smooth our growth, while we continue to expand our overall corporate gross margins and reduce cost and cash burn. Now, let’s dive into our quarterly performance and some highlights from our product portfolio. In the first quarter, on a pro forma combined basis, we have served revenue growth of roughly 2% year-over-year. This is 80% revenue growth on an as-reported basis year-over-year, with the impact of SomaScan revenue in 2024. This is largely in line with our expectation, considering the aforementioned ongoing macroeconomic challenges impacting the life science industry, which extended sales cycles, which again pushed some instrument purchases beyond Q1. Importantly, with the benefit of cost rationalization, we delivered a 26% reduction in non-GAAP operating expenses and 45% adjusted EBITDA improvement on a pro forma combined basis. This is the power of the Standard BioTools model, actively pursuing M&A as an augmentation to organic growth, building scale in a highly fragmented space and using that to achieve operational leverage. Our expanded portfolio offers product across multiple distinct product categories, including instruments, consumables, field-based service, and now our SomaScan service. To give you a sense of our sales mix this quarter, on a pro forma combined basis, instruments accounted for approximately 11% of revenue in Q1, consumables and kits made up 40%, instrument support services 13% and SomaScan services 34%. Importantly, our combined recurring sources of consumable and instrument support services revenue bolstered by our expansive service and kit offerings represented about 90% of total revenue, which served as a nice offset to softer capital equipment purchases. While our SomaScan business is still concentrating on a few handful of key pharma accounts, where revenue can be lumpy and is dependent on timing of projects and available budgets, these expanded revenue sources further enhanced our diversification. And the more diversified we become, the better we can navigate capital cycles like the we currently — like the one we currently find ourselves operating in. Furthermore, these offerings cater to a broad customer base across academic research and biopharma, positioning us well for sustained growth in these large and attractive markets. We believe the key opportunity to leverage our combined technology platforms for future offerings, particularly expanding our existing lab service business into a multimodality offering, providing customers premium data with clinical solution support in a model, we call, multi-omics as a service. This approach is a natural of — extension of what we are and provides a quicker path to technology adoption, while avoiding some of the capital budget constraints currently facing the broader biopharma market. We are also exploring new models to selling SomaScan both with a lower plex, more cost effective model and a single SOMAmer reagents. Of the most exciting is the early [indiscernible] traction from our partnership with Illumina, which will broaden market access through the Illumina NGS partnership. We are off to a strong start and Illumina began its early access program with a small number of customers in the first quarter. Early feedback has been overwhelmingly positive. As a reminder, this jointly developed product allows customers to run the highest plex SomaScan at — utilizing the installed base of NovaSeq as an NGS readout. As demonstrated by our successful Authorized Sites program, there is clear demand from our customers to be able to run the assay on a distributed basis or kits basis. The teams from both companies are working closely together, and Illumina is on track for a full commercial release in early 2025. Standard BioTools is a true enabler for scientists, allowing them to answer the most difficult questions they have. While we focus on building omic solutions, our job is to supply services, instruments and consumable for researchers to produce the omic answer that’s relevant to their scientific question. This is how we fundamentally look at our business and business units. If you look at our business today through an omic lens, our performance was as follows. Polyomics accounted for roughly 80% of our total revenue this quarter, representing a 3% increase year-over-year. We continue to lead with the industry’s most comprehensive and differentiated polyomics platform, comprising high-plex plasma polyomics, flow cytometry and spatial biology. Despite the modest year-over-year growth, we have a high conviction that these technologies represent exciting near and long-term growth opportunities due to their innovative applications and strong end market demand. Our genomic solutions are currently in decline and, as discussed before, we manage our legacy microfluidic solution for profitability, not growth. While down 6% year-over-year, the bright spot is our strategic transition to use this technology as an OEM provider and strategic enabler to a core set of customers, including another leading polyomics company which currently has approximately 200 of the OEM instruments in the field, which are again dependent on our microfluidics consumables. Finally, we have been laser-focused on strategic capital allocation to drive long-term value creation. We are committed to targeted investment in our existing technologies and platforms and to M&A, of which we have a full pipeline of potential partners. We also preserve shareholder value via share buybacks and opportunistically simplifying our capital structure. To that end, in mid-March, we announced an agreement with our two largest shareholders, Viking Global and Casdin Capital, to exchange all outstanding shares of their Series B convertible preferred stock for shares of common stock and eliminated all associated Series B preferred rights and privileges. Coupled with our share buyback, these actions represent major steps forwards in streamlining and simplifying our capital structure, which we believe will ultimately make us more attractive to new long-term investors and potential M&A partners. Standard BioTools today is a growing leader in the life science tools sector, which remains fragmented, underresourced and, for most companies, unprofitable. Today, I’m excited to address you as a unified company with a fortified balance sheet, diverse product mix and a scale platform that integrates critical life science solutions under one roof and equally important on a firm path to profitability in early ’26. Looking ahead, we are reaffirming our full year revenue guidance of $200 million to $205 million for ’24 and we are on track to achieve approximately $300 million in revenue in 2026. I’ll now turn the call over to Jeff to discuss our financial results in more detail. Jeff?
Jeff Black: Thank you, Michael, and thank you all for joining our call today. As a reminder, our first quarter results on an as-reported basis include the combined operations of Standard BioTools and SomaLogic since the close of the merger on January 5th of this year, while the first quarter of 2023 as-reported includes the financial results of the Standard BioTools legacy business only. So, for comparative purposes, we think it’s much more meaningful to look at the combined results of operations for both businesses. So my commentary today will focus on the pro forma combined results for both Standard BioTools and SomaLogic for both the first quarter ’23 and ’24, and that includes the stub period between January 1st, ’24 and the close of the merger on January 5th. As a reminder, please refer to today’s press release and the appendix to our investor deck for more information, including a reconciliation of GAAP to the non-GAAP measures I’ll be discussing here. So, starting off with revenue in the first quarter, our pro forma combined revenue was just over $46 million. It grew about 2%, as Michael said, largely in line with expectations and, again, all while continuing to navigate the lingering headwinds from a challenging macroeconomic environment. The SomaScan-related business contributed about $24 million in revenue for the quarter, grew over 20% and that’s on healthy demand from SomaScan customers, growth in our kits business to Authorized Sites, and the initiation of the early access program with Illumina, which, as Michael mentioned, is on track for a full commercial launch in 2025. And again, not only do we see the SomaScan-related business as a growth driver for us, it’s also a valuable source of revenue diversification for the combined business, and we saw that reflected in our first quarter results. On the Standard BioTools instruments, consumables and instrument support services side of the business, revenues were $22 million, down 12% over last year, and that’s due primarily to the lingering economic headwinds we mentioned, most notably impacting capital budgets in both biopharma academic research as well as continuing pressure outside the US. With that said, we do see a robust and growing pipeline of opportunities. We expect a return to growth in the second half of 2024 as macroeconomics are expected to improve and budgetary constraints begin to lift. Overall, consumables and services in both proteomics and genomics were impacted by our pre-2023 declines in our legacy installed base and we do expect to see pull through begin to expand in late 2024 as our ’23 and ’24 installations continue to ramp up. Proteomics as a whole was up 3% year-over-year, while genomics was down 6% as we continue to manage this business through its planned transition. We’ve now rightsized our operating expenses in genomics to a positive contribution margin and will continue to drive profitable growth in that segment. Moving on to our operating performance. On margins, our non-GAAP gross margin on a pro forma combined basis expanded by 300 basis points from 53% to 56%, and that’s driven by a combination of product mix and pricing. But it’s also important to note here that this also includes over 350 basis points of offset due to the classification of certain operations, services and quality related operating expenses that we moved into COGS to align accounting policies between Standard BioTools and SomaLogic as a result of the merger. So we expect this will have a similar impact for the full year gross margin in 2024. As we stated before, we continue to make significant strides in aggressively managing residual headwinds related to legacy service and warranty related costs. Often on a customer-specific basis, we expect this could continue to create pressure throughout 2024, but we continue to remain confident in our ability to drive our non-GAAP gross margins into the mid-60s over time, especially as we move past these transitory headwinds, we grow sales and we drive cost improvements through continued deployment of SBS and lean principles across our combined operations. Moving to operating expenses, very pleased to report that we’re ahead of plan on our operating expense reduction initiatives. On a combined pro forma basis, non-GAAP OpEx of just over $49 million decreased by about $17 million or 26%, and that just reflects early traction on expense reduction initiatives that began in the second half of last year. Keep in mind that our first quarter OpEx exclude about $1.7 million of expenses related to the classification of OpEx and the COGS, as I mentioned. But even excluding this impact, our combined non-GAAP operating expenses were down over $15 million or 23%. And that’s before we see any impact from the operational restructuring initiatives that we recently implemented. And as a reminder on overall cost out, we’ve previously announced our intention to remove $80 million in non-GAAP operating costs as compared to, we call, our jumping off point of $250 million, which was our annualized OpEx based upon the combined first half 2023 run rate. We broke out that target reduction as follows, $40 million in G&A, $20 million in R&D, and $20 million in sales and marketing. We also previously announced that we expect to achieve the full $80 million in annualized cost synergies by fiscal ’26 and that we would have at least 50% or $40 million of that operationalized in 2024 with the full P&L impact of those savings reflected in ’25. Based upon our recently announced reorganization and restructuring initiatives, we now expect to have operationalized $50 million in annual operating expense savings for the full year in 2025, with $40 million to $45 million coming from SG&A and $5 million to $10 million from R&D, and that’s net of a number of planned focused reinvestments. And finally, to avoid any confusion on this, these OpEx savings are in addition to the reclassification of the $7 million to $8 million in annual OpEx into COGS that I mentioned before. So, in total, we expect that approximately $20 million to $25 million of these savings will show up in the P&L in 2024 and the full P&L impact will be reflected in 2025. So, based upon these efforts, we are very enthusiastic, more than ever, about the value we expect to generate under our now combined cost structure, leveraging the scale and reach of our portfolio, and managing to a positive adjusted EBITDA target in 2026. But at the same time, we’ll continue to maintain focused investments in commercial organization and our R&D pipeline to support sustained long-term revenue growth. That brings me to cash flow and the balance sheet. We ended the first quarter with about $464 million in cash equivalents, restricted cash and short-term investments. As expected, cash burn was unusually high in the quarter due to several merger-related and other non-operating uses of cash. In the aggregate, during the first quarter, we made about $70 million in cash payments for settlement of year end operating accruals, merger-related expenses, term debt retirement and share repurchases. Excluding the impact of these items, our adjusted operating cash burn was about $29 million and that represents about a $5 million or 14% reduction over pro forma combined burn a year ago. And this is before the impact of any of the cost initiatives we recently announced. And we also think it’s important to note that some of this quarter burn is a function of the timing of payments for merger transaction costs. Just as a reminder, when we announced the merger last October, we gave an expected 2023 year end cash outlook of around $500 million. We actually ended the year at $565 million, with a big driver of this difference being payments that we expected to make in ’23 that were pushed into the first quarter. So, we expect our operating cash burn over the next few quarters will reduce significantly. While not at the levels that we saw in the first quarter, we do expect continued cash outlays for merger-related costs, restructuring activities, as well as additional share buybacks we’ve executed since the end of the first quarter before having recently terminated that program. We’re well positioned to fund both these non-operating cash needs and to support the combined business to cash flow breakeven, again, our target of 2026. And as we think about any future funding under — for M&A, you can remain assured that we’ll be thoughtful about additional strategic M&A when such opportunities arise, including the related use of cash. And one final update on our capital structure initiatives. As we previously announced in February, the Board approved a new share repurchase program of up to $50 million. With our enhanced balance sheet, this has enabled us to repurchase common shares to offset future dilution from possible future equity issuance rising from our convertible debt and other instruments in our cap structure. We actually saw this as really nothing more than responsible housekeeping, providing flexibility to preserve long-term shareholder value. Including the $11 million in share buybacks through our first quarter, year-to-date, we’ve purchased approximately 13.6 million shares or about 3.5% of our common outstanding shares for a total of about 36 million in cash at an average repurchase price of $2.68 per share. While we still have room available under the $50 million plan that was authorized by the Board, we did terminate the existing buyback plan on May 2nd. So, in summary, we’re executing operating and financial objectives. We remain responsible stewards of our assets and we remain committed to create long-term value for our shareholders. And with that, I’ll turn the call back to the operator for Q&A.
Operator: Yes. Thank you. We will now begin the question-and-answer session. [Operator Instructions] And the first question comes from Matt Stanton with Jefferies.
Matthew Stanton: Hey, thanks. Maybe first one for you, Michael. I think you talked about the early findings from Illumina as overwhelmingly positive. Can you maybe just talk a little bit more about what the initial feedback has been and then some of the important proof-points from here and how should we — we should start to think about the commercial launch into ’25? Obviously, you don’t flip a switch. So, onboarding, ramping up, things to think about. And then in terms of contribution to Soma in 1Q, is there any way to quantify what the Illumina early access contributed, if you guys maybe want to share that? Thanks.
Michael Egholm: Yeah. I’ll let Jeff follow up on the last part of the question. So, the teams have been hard at work for quite a while at this. And so, putting a version of the 7K in the hands of customers was the first leap and essentially able to reproduce what we’ve been doing internally and at a very like maintaining that very high hit rate on many proteins and a low CV, which is what differentiate us. The full launch will be in early ’25 is what Illumina is communicating so far and will be based on the 11K assay. I’ll say I’m personally much more — even more enthusiastic of this relationship than I was a few months when I stepped in as I’ve seen the early readout in the data and also seeing the value in having a partner like Illumina with the market reads that they have, which, of course, far, far exceeds ours. And then you had a question here on the timing transitioning, we’re still working through that, but net-net, we believe this is going to be a long-term growth driver. Maybe also just as a reminder, there was a $30 million payment upfront, which basically still sits on our balance sheet as unrecognized, unrecognized revenue. And so, anything to add, Jeff, on?
Jeff Black: Yeah. To your question, Matt, on Illumina, we don’t break out revenue specific to Illumina separately, but I can tell you it’s still early stages. It’s a handful of customers. It’s in the, call it, very low millions. Very low single millions.
Matthew Stanton: Okay, great. That’s helpful. And, Michael, you talked about some of the updates coming out of the strategic planned readout, some newer growth opportunities around multi-omics as a service, low plex or single SOMAmer reagent models. Can you just talk about kind of timing around those as we think of those as new growth opportunities and any investments or costs associated with getting those off the ground here?
Michael Egholm: Yeah. So, first off, no — thanks. Good. Very good question here. As we are reporting it now, any investments we are making, like the cost savings we projected here so far, $50 million operationalized and we’ll see it flow through here by the end of the year, is net of investments that we are making in those initiatives. So, it’s a really important thing to note. And our strategic review confirmed and highlighted a number of tweaks to the strategy. Number one was that SomaScan is highly, highly invented. And unlike any other technology we see out there, it’s scalable, in that as we expand content, we maintain our low CVs and do not increment complexity or cost. And that means that we’re going to keep investing in that engine to expand that content and put a distance between us and further distance between us and the competition. Secondly, we saw a very, very high customer demand for individual SOMAmer. And we’ve got to recognize that SOMAmers, they’re not like antibodies, but they are just another affinity reagent, just like an antibody with the same approximate affinity and specificity. And we have 11,000 monoclonal human affinity where 11,000 affinity reagents for human proteins. And we believe this represents a unique opportunity. We’re going to start small and we’re going to start operationalize it here by the middle of the year initially to our current customers and then offer it up much more broadly. So, we think there’s a very strong pull internally, but also — from current customers, but we’re even beginning to see a much broader opportunity with SOMAmer as being a routine reagent used to as orthogonal validation to antibodies and/or be another thing up a researcher’s sleeve when they cannot make an antibody work. And then the third piece that we recognized was around the value of the service we run. We run a very sophisticated service that works with very sophisticated customers and COOs. And so, we have the whole workflow from getting the cost — from getting all the samples from COOs, running them quickly, getting bioinformatics analysis and clinical guidance back to our customers. And we expect to lean into this and add some of the other products that we have. Most obviously our flow cytometry solution, which we think will be highly synergistic. And last but not least, we’re already, as I briefly alluded to in the script, beginning to look at how we can combine our microfluidics solution as a readout and maybe longer-term expand on the workflow. So, maybe longer answer than what you were asking for, but we’re excited here after the strategic review.
Matthew Stanton: Appreciate that. That’s really helpful. I guess, just last one, sticking with you, Michael. In terms of capital allocations related to M&A, you talked about a pretty healthy pipeline. Just talk about appetite for deals, maybe potential size of deals and just the general bandwidth of the team, given the Soma integration and a lot of other heavy lifting you guys are doing behind the scenes. Thank you.
Michael Egholm: Yeah. So, integration and successful integration is job number one, two and three. Having said that, I did build out a very strong team here over the last two years, so there’s definitely capacity in the team, and we can walk and chew gum at the same time. Secondly, as I’m sure you are all well aware, there’s a really upheaval in — here in the venture funded part of the market. And we’re seeing ever more interesting assets being eager to work with us or eventually to be acquired for us. So, we’ll be highly disciplined and opportunistic, and we will, for sure, just on the size, we won’t do anything that’s so big that it burns down on the very significant buffer we have between where we are now and profitability. And we’ll keep working the bigger deals. As everyone know from the disclosures, we worked on the SomaLogic deal, what was a year and a half plus, and so we’ll keep doing that.
Matthew Stanton: Super. Thank you.
Operator: Thank you. And the next question comes from Dan Brennan with TD Cowen.
Daniel Brennan: Great. Thank you. Thanks for the question, guys. Congrats on the quarter. Maybe just kind of high level just on the guide for the year. Obviously, Michael, you talked about some of the CapEx challenges. The first quarter was kind of a little bit better than you guys expected, but it does imply a nice steep ramp in the back half. So, just any thoughts on, like, Q2? I think consensus sits at $48 million. Any thoughts that that’s about right. And then as we think about, like, the growth that’s implied in the back half of the year, I guess, kind of what can you say about either visibility or just some of the assumptions there?
Michael Egholm: Yeah. So, we are confident in the long-term, even the mid-term growth here. So, we are navigating, as we talked to all of you about here over the last few months. So, a number of transitory headwinds, one of them being this very, very tough CapEx market as I’m now seeing all our peer companies report as well. So, what confidence do we have? We’re seeing our sales funnels are getting larger. I have not seen any cancellations. I’ve only seen purchases being pushed out. And then we’re getting all or some of the headwinds we had. And then last but not least, at the AACR here last month, we launched sort of the next extension on our Hyperion XTi, new imaging modes with lightning fast, and we launched a long awaited slide loader, which can take 40 slides and customers could crank through those in 24 to 72 hours. I would add here, we’re the only polyomics platform that need a slide loader out there. So, very excited on the progress and excitement around that. And then last but not least, as we have talked about on the legacy Standard Bio side, our site of flow, there were a number of issues we’re working through and we’re really getting confident in the solution and see this — our ability to chip away of what is a very big flow market that will with time — or part of that market will transition to high parameter flow. And to that end, at the CYTO meeting, I think it’s — actually, it was yesterday, CYTO meeting in Edinburgh, there was work presented by one of our collaborators to show that not only do we have fast panel design up to 50 markers, we are hugely advantaged over any other technology on looking at intracellular markers such as cytokines. And that really, if you want to study that biology, which is really important, we are really the only solution. All that give us hope for the back end and for ’25 and ’26.
Daniel Brennan: Okay, great. And then I know a question or two already on SomaLogic, but really strong quarter, up almost 20%. Some of our diligence reflected that could be hitting a nice growth inflection here despite the challenging market. So is that kind of growth sustainable for the year do you think? Just any color, kind of what you saw? I know you talked a lot about the Illumina partnership for ’25, but kind of the driver today on SomaLogic and then kind of just kind of growth sustainable for the year?
Michael Egholm: As I noted in my script, we see really like strong validation for our assay out there. We’re aware of a couple of bake-offs that will be reported out soon with our major competitor, which is hugely favorable to us. So, long-term, we’re really bullish on this. The big customers we have in pharma are all project-based and subject to sample availability and budget availability. And we still — while we have a view to move more to translational research, where funding typically is not as temperamental as in discovery, we’re still mostly in discovery. So, I don’t really have a good answer for you there, so — but we love the quarter we just had here on the legacy SomaScan side.
Daniel Brennan: Great. And maybe one for Jeff just in terms of the OpEx leverage. Nice leverage in the quarter. Can you give us some thoughts on the pacing of the OpEx through the year and how do the synergies flow in kind of as we get towards the back half of the year?
Michael Egholm: Yeah, I’ll hand that one over to Jeff.
Jeff Black: Yeah, Dan, great to hear from you. So, as I said, we’ve, what I’ll call, operationalized $50 million in savings. And so, we expect to see the full P&L impact of that $50 million for the full year ’25. That will start to layer in really second half of the year. So, we expect that we’ll see, call it, $20 million to $25 million of that actually hit the P&L in the second half of the year. So, in the P&L, you’ll see somewhere around 40% to 50% of that $50 million reflected in ’24.
Daniel Brennan: Great. Okay. All right.
Jeff Black: You’ll see primarily — you’ll primarily see it come out of SG&A.
Daniel Brennan: SG&A. Okay. All right. Well, great, guys. Thank you very much.
Operator: Thank you. And the next question comes from Paul Knight with KeyBanc.
Paul Knight: Hi. Congratulations on what must’ve been a lot of work to put this number set together.
Michael Egholm: Thanks, Paul.
Jeff Black: Thanks, Paul.
Michael Egholm: Thank you.
Paul Knight: The color you put out earlier on this SomaScan early partnership on NGS, obviously, Olink has a readout on NGS that’s getting a lot of traction as well. Are you going to be competitive with the Olink technology on the NGS readouts?
Michael Egholm: Yeah. So, maybe just for background, SomaLogic in the past stepped away from the market for a three-year period, which gave an opening to Olink, which they executed beautifully on and, therefore, have many, many more sites up and running than we have. Our solution together with Illumina is highly competitive and it — really, the advantage really lies in the SomaScan assay, which I alluded to it before, but the underlying advantages that our technology is scalable, we see many, many more proteins and we see them at a much, much lower CV, which means that the discovery power of our assay is manifold larger than that of Olink’s. And without discussing cost, but they’re sort of in the same ballpark. We think we are highly advantaged in the long-term. And I also alluded to bake-offs to be published here over the next year.
Paul Knight: Okay. And then on the genomics side, you obviously supply some OEM partners in the marketplace. Do you see yourself really linked long-term as supplying the microfluidic technology years out, Michael?
Michael Egholm: Yes. We actually believe it’s a highly differentiated solution. It’s a very high performing solution, for certain. There’s certain sample/complexity points that it’s a really good solution. One of them is we are an OEM partner to that other polyomics company there and they — like, as best as we can estimate, they must have something approaching 200 units out in the field that are still reliant on our proprietary consumables, the integrated fluidic circuit. So, with what we have today, we actually feel really good about the business. We certainly expect to be as good partners to Thermo once that acquisition closes and don’t expect a change there. But if there should be one, as I said, we already have 200 units out there that will consume the IFC. So, feeling really good about that. And as we recently announced, we added a second OEM relationship, Next Gen Diagnostics. We’re very excited about the prospect there. It won’t yield anything fast here, but in a few years, this will be a very nice growth and profit driver. And rest assured, we are working on additional OEM relationships. As I said, nothing there happens fast, but once they’re off and running, highly, highly accretive.
Paul Knight: Okay. And I guess, Jeff, my last question would be the $71 million cash payments, that includes, you said, $11 million of the share buyback?
Jeff Black: Yeah. Yeah. So, it’s $11 million in share buyback, $8 million in, we retired our Silicon Valley bank debt and then $30 million, $34 million in merger and there was an elevated amount of payments that we’re paying off year end accruals, which is pretty typical in the first quarter. So we think about our adjusted operating burn more in that $29 million, $30 million range.
Paul Knight: Okay. And kind of flat similar in 2Q?
Jeff Black: Yeah. I think that’s right. I mean, like I said, in terms of kind of normalized adjusted operating burn, yes. We do expect we’ll continue to have some merger-related cash payments, but nothing to the level that you saw in the first quarter.
Paul Knight: Okay. Thank you.
Operator: Thank you. And this concludes our question-and-answer session. I would like to return the conference to Michael Egholm for any closing comments.
Michael Egholm: Okay. Thank you, operator. I’ll close by once again thanking our team for their continued execution and dedication to our mission and to our investors for your continued support. I continue to be ever mindful of the work and challenges ahead, but remain more excited and confident in our ability to empower research to change patients’ lives and, in turn, create value for our stakeholders. Stay tuned for future updates. We look forward to connecting with many of you at the upcoming Jefferies, Cowen and Scotiabank conferences in June. And I’ll now turn the call over to the operator to conclude the call.
Operator: Yes. Thank you. The conference has now concluded. Thank you for attending today’s presentation. You may now disconnect your phone lines.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
Read the full article here
